IBI311 (Tetuzumab) Phase 4 Trial Initiated for Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Abstract
IBI311 (Tetuzumab) is undergoing a Phase 4 trial to evaluate safety and efficacy in active moderate-to-severe TAO, comparing it against sequential hormone therapy.